Poly(ethylene glycol) (PEG) conjugated arginine deiminase: Effects of PEG formulations on its pharmacological properties

Journal of Controlled Release

Volumn 80, Issue 1-3, 2002, Pages 259-271

  Holtsberg, Frederick W ^a   Ensor, Charles Mark ^a   Steiner, Marion R ^b   Bomalaski, John S ^a   Clark, Mike A ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Arginine; Arginine deiminase; Pharmacodynamics; Pharmacokinetics; Poly(ethylene glycol)

Indexed keywords

ARGININE; ARGININE DEIMINASE; MACROGOL;

ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME BINDING; IMMUNOGENICITY; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIGENS; AREA UNDER CURVE; ARGININE; CHEMISTRY, PHARMACEUTICAL; ESCHERICHIA COLI; FEMALE; HALF-LIFE; HYDROLASES; MICE; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RABBITS;

EID: 0037161333     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(02)00042-1     Document Type: Article

References (33)

1. Asparaginase as a drug for treatment of acute lymphoblastic leukaemia
2. Use of L-asparaginase in childhood ALL
3. Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line
4. High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro
5. Anti-tumor activity of arginine deiminase from Mycoplasma arginini and its growth-inhibitory mechanism
6. Antitumor activity of tumor necrosis factor-α conjugated with polyvinylpyrrolidone on solid tumors in mice
7. Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis
8. Chemical modification by polyethylene glycol of the anti-tumor enzyme arginine deiminase from Mycoplasma arginini
9. In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini
10. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation
11. Controlled-release, pegylation, liposomal formulations: New mechanisms in the delivery of injectable drugs
12. Cloning and expression of a prokaryotic enzyme, arginine deiminase, from a primitive eukaryote Giardia intestinalis
13. Development of pegylated interferons for the treatment of chronic hepatitis C
14. Chemical modification and cleavage of proteins and chemical strategy in immunochemical studies of proteins
15. 1H-NMR spectroscopy and conformation of the conjugates
16. Modification of E. coli L-asparaginase with polyethylene glycol: Disappearance of binding ability to anti-asparaginase serum
17. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates
18. Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates
19. Nucleotide sequence of the arginine deiminase gene of Mycoplasma hominis
20. High-level expression of Mycoplasma arginine deiminase in Escherichia coli and its efficient renaturation as an anti-tumor enzyme
21. Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct
22. Toxicologic studies of a conjugate of asparaginase and polyethylene glycol in mice, rats, and dogs
23. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid
24. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
25. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein
26. Therapeutic proteins: A comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(N-acryloylmorpholine)
27. Pegylation: A novel process for modifying pharmacokinetics
28. Citrullinemia: A new case, with implications concerning adaptation to defective urea synthesis
29. Acute neonatal and benign citrullinaemia in one sibship
30. Neurologic outcome in children with inborn errors of urea synthesis. Outcome of urea-cycle enzymopathies
31. Intrafamilial phenotypic variability in citrullinaemia: Report of a family
32. Preparation of recombinant argininosuccinate synthetase and argininosuccinate lyase: Expression of the enzymes in rat tissues